User: Guest


Global Market Trajectory & Analytics




Number of executives repeatedly engaged by snail & email outreach


Interactions with Platform & by Email


Unique # Participated


Responses Validated*
* Login to view program details and full enterprise executive list.


JUL 2020








USD $5450

Amid the COVID-19 crisis, the global market for Intravenous Immunoglobulin (IVIg) estimated at US$10.3 Billion in the year 2020, is projected to reach a revised size of US$15.7 Billion by 2027, growing at a CAGR of 6.2% over the analysis period 2020-2027. IgA, one of the segments analyzed in the report, is projected to record a 6.8% CAGR and reach US$5.8 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the IgD segment is readjusted to a revised 6% CAGR for the next 7-year period.
The Intravenous Immunoglobulin (IVIg) market in the U.S. is estimated at US$3 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.8 Billion by the year 2027 trailing a CAGR of 5.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.9% and 4.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5% CAGR.
In the global IgE segment, USA, Canada, Japan, China and Europe will drive the 6.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.6 Billion in the year 2020 will reach a projected size of US$2.4 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.8 Billion by the year 2027.We bring years of research experience to this 17th edition of our report. The 222-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
Bharat Serums and Vaccines Limited; Biotest AG; China Biologic Products, Inc.; CSL Limited; Grifols, S.A.; Hualan Biological Engineering Inc.; Kedrion S.p.A.; LFB Group; Octapharma AG; Shanghai RAAS Blood Products Co., Ltd.; Shire plc; Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
» Type (IgA, IgD, IgE, IgG, IgM) » Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Other Applications) » End-Use (Hospitals, Clinics, Homecare Settings) » Segment (Intravenous Immunoglobulin (IVIg))
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World


Users of our portal have insider access to our data stacks based on project relevance and engagement status. Tiered access is offered to data stacks, managed based on user status - Opt-in, Active Panelist, Inactive Panelist, Active Client or Inactive Client.







Registration is required to access our data stacks.


Registration is required to access our data stacks.


Registration is required to access our data stacks.


We are firmly committed to build upon perspectives from global executive insights. These engagements enrich our projects. Our primary research programs are fully validated and accessible by clients. (Its a common industry-wide* practice that no validated primary research is done! For the most part, remote resident analysts curate and write reports drawing on search engine research and data modeling.

* A review of 262 off-the-shelf market report publishers worldwide.

Client companies can access multiple features on our MarketGlass™ platform.

Clients have full-stack insider access to our ongoing primary research program. We have a very successful incentive driven primary research program that benefits participating executives regardless of their purchase decision. Our platform presents a unique opportunity to collaborate with peers and review competitors’ inputs and response clusters.

Detailed engagement stats are presented for every company and executive contacted. This is made available for our client reviews. (no other publisher offers this!)

A full-stack access to clients of all primary and secondary source content. This can often run into thousands of pages.

Where relevent and possible we present competitive brands.

Peer-to-peer online interactive collaborations. Allows for team curated bespoke analytics.

Customers can update and build bespoke versions of our analytics. Bespoke updates are fulfilled within a two-day turnaround.

Discretely bounce off queries to participant pool of executives. Our embedded AI selectively pings participants geographically and by domain acumen.

We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.

Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.

All updates are offered for one year from date of your purchase without charge. Clients can opt for annual auto renewal and stay current without interruption.

Immunoglobulins to See Steady Growth
Recent Market Activity
Intravenous Immunoglobulin - A Proliferating Biologic
Application Areas - A Brief Review
Market Outlook
Growth Drivers and Market Challenges
Competitive Scenario
Grifols Continues to Consolidate Market Position
CSL Sees Robust Growth in Immunoglobulin Franchise
Shire Continues to Invest Big in Immunoglobulins
Bivigam Changes Hands Consequent to Unexpected Turn of Events
Global Competitor Market Shares
Intravenous Immunoglobulin (IVIg) Competitor Market Share Scenario Worldwide (in %): 2018 & 2025
Impact of Covid-19 and a Looming Global Recession
Bharat Serums and Vaccines Limited (India)
Biotest AG (Germany)
China Biologic Products, Inc. (China)
Guizhou Taibang Biological Products Co., Ltd (China)
CSL Limited (Australia)
Grifols, S.A. (Spain)
Hualan Biological Engineering Inc. (China)
Kedrion S.p.A. (Italy)
LFB Group (France)
Octapharma AG (Switzerland)
Shanghai RAAS Blood Products Co., Ltd. (China)
Shire plc (Ireland)
Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd (China)
Strong Demand from Major Indications and Pipeline SCIg Products to Fuel Growth of Immunoglobulins
Increasing Awareness of Primary Immunodeficiency Disease to Drive IVIg Market
IVIg - The Mainstay of PI Therapy
Subcutaneous IG Formulations Gain Therapeutic Foothold
Hyperimmune Globulin - Taking IVIg Therapy a Step Ahead
Unsuccessful Clinical Trials for Alzheimer's - A major Setback for IVIg Market
Synthetic Replacements to IVIg Therapy
IVIg Therapy - Home-based vs. Outpatient Settings
Per Capita Consumption Rate Varies Across Countries
Favorable Reimbursement and High Usage make US the Largest Consumer
Growing Adoption of Screening Programs to Reduce Usage of Immunoglobulins in the Treatment of SCID
Aging Global Population: Major Opportunity Indicator
Improving Healthcare Expenditure to Foster Growth
Total Companies Profiled : 24

Click here to request a full table of contents and more details on this project.



Registration is required to access our data stacks.


Panelists are carefully chosen based on their domain expertise and market influence.

Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.

Our panelists give 30-minutes a month or a one-time 30-minute participation based on their time and willingness.

  • Complimentary previews of full stack research data for participated
  • Insider access to research programs including engagements and stats from other panelists
  • Unlimited research credits of $1000 per participated project
  • Competitive Intelligence Alerts including engagements from other panelists and validated participants worldwide relevant to your company
  • Interact with other panelists via our MarketGlassTM Data Exchange Platform*
  • BlogX - Panelists can use our blogging platform publish their viewpoints on news relevant to their domain expertise. Platform enables panelists to share their viewpoints on current news and events related to their areas domain expertise with timely and insightful blogs*

* Complete details will be shared with panelists upon formal acceptance.



Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: